O'Dwyer, Michael E <br/><br/>
Clonal evolution and lack of cytogenetic response are adverse prognostic factors for hematologic relapse of chronic phase CML patients treated with imatinib mesylate.  [electronic resource] 

 -  Blood  Jan 2004 
 - 451-5 p.  digital 
<br/><br/> Publication Type: Clinical Trial; Clinical Trial, Phase I; Clinical Trial, Phase II; Journal Article; Multicenter Study 
<br/><br/><label>ISSN: </label>0006-4971 
<br/><br/><label>Standard No.: </label>10.1182/blood-2003-02-0371  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Adult<br/>Aged<br/>Benzamides<br/>Blood Cell Count<br/>Dose-Response Relationship, Drug<br/>Female<br/>Humans<br/>Imatinib Mesylate<br/>Immunosuppressive Agents--therapeutic use<br/>Interferons--therapeutic use<br/>Leukemia, Myelogenous, Chronic, BCR-ABL Positive--drug therapy<br/>Male<br/>Middle Aged<br/>Piperazines--therapeutic use<br/>Probability<br/>Prognosis<br/>Pyrimidines--therapeutic use<br/>Recurrence<br/>Treatment Failure